CagriSema vs MOTS-c
Overview
CagriSema and MOTS-c are both weight management & metabolic peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares CagriSema and MOTS-c across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| CagriSema | MOTS-c | |
|---|---|---|
| Category | Weight Management & Metabolic | Weight Management & Metabolic |
| Regulatory status (US) | Research use only | Compounding (Rx) — Apr 2026 |
| Typical dosage | Clinical trials | 5-10 mg |
| Frequency | weekly | weekly |
| Reported benefits | Superior weight loss results, metabolic optimization | Enhanced metabolism, improved insulin sensitivity, increased exercise capacity, longevity benefits |
| Reported side effects | Under study | Well-tolerated. Minimal reported side effects |
Key differences
Primary use. CagriSema is categorised under Weight Management & Metabolic, while MOTS-c falls under Weight Management & Metabolic. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. CagriSema: not FDA-approved; treated as a research compound. MOTS-c: not FDA-approved; compounding permitted with a prescription as of April 2026.
Dosing. CagriSema is typically dosed at Clinical trials (weekly). MOTS-c is typically dosed at 5-10 mg (weekly).
Can you stack them?
Some protocols combine peptides, but stacking CagriSema and MOTS-c has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between CagriSema and MOTS-c?
- CagriSema and MOTS-c are both weight management & metabolic peptides, but they differ in mechanism, dosing, and regulatory status. CagriSema is not FDA-approved; generally classified as a research compound, whereas MOTS-c is not FDA-approved; compounding permitted with a prescription (as of April 2026).
- What is CagriSema used for?
- Combination therapy.
- What is MOTS-c used for?
- Mitochondrial optimization.
- Can you take CagriSema and MOTS-c together?
- Some users combine peptides within a single protocol, but stacking CagriSema and MOTS-c has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is CagriSema or MOTS-c FDA-approved?
- CagriSema is not FDA-approved; generally classified as a research compound. MOTS-c is not FDA-approved; compounding permitted with a prescription (as of April 2026).